Loading...
•
Mar 31, 2024
Enliven Therapeutics Q1 2024 Earnings Report
Reported first quarter financial results and provided a business update.
Key Takeaways
Enliven Therapeutics reported positive proof of concept data from the Phase 1 clinical trial of ELVN-001 in CML, achieving an initial cumulative MMR rate of 44% by 12 weeks in response-evaluable patients. The company's cash, cash equivalents, and marketable securities totaled $320.5 million, which is expected to provide cash runway into late 2026.
Announced positive proof of concept data from Phase 1 clinical trial of ELVN-001 in CML, achieving a 44% cumulative MMR rate by 12 weeks in response-evaluable patients.
Advanced trials of ELVN-002, including activating the first site to evaluate ELVN-002 in combination with trastuzumab in patients with HER2+ cancers.
Entered into a securities purchase agreement for a private investment in public equity (PIPE) financing resulting in gross proceeds of $90 million, extending cash runway into late 2026.
Cash, cash equivalents and marketable securities totaled $320.5 million as of March 31, 2024.
Forward Guidance
Enliven Therapeutics expects Phase 1b data in 2025, and Phase 1 monotherapy data, Phase 1a/b Herceptin combination data in HER2+ CRC, and initial Phase 1a combination data in HER2+ MBC are expected in 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...